Drug
Capmatinib clinical trials
Also written INC280, Tabrecta and INCB28060.
- studies test it
- 44
- open now
- 4
- in phase 3
- 5
- first study started
- 2010
Keep track of what changes. Save the capmatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
44 studies that test it; most in 2015 (10)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 10 |
| 2016 | 5 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 18
- Phase 2
- 27
- Phase 3
- 5
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 29 · Other 15
Novartis Pharmaceuticals (26) · Cancer Research UK (2) · Janssen Research & Development, LLC (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Pfizer (1) · SCRI Development Innovations, LLC (1) · National Cancer Institute (NCI) (1) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Ceritinib (3) · Trametinib (2) · Olaparib (2) · Futibatinib (2) · Binimetinib (2) · Ribociclib (2) · Spartalizumab (2) · Erlotinib (2)
Studies
Open first, then newest update. How each study uses capmatinib is read from its arms, and is right about nine times in ten.
Testing it · 44
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Capmatinib
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886Written as Capmatinib
- DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET DysregulationsRecruitingPhase 2/3Cancer Research UKNCT06988475Written as Capmatinib
- Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 MutationsNot yet recruitingPhase 2Sun Yat-sen UniversityNCT06054191Written as Capmatinib
- Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.CompletedPhase 4Novartis PharmaceuticalsNCT05110196Written as Capmatinib 150 mg
- A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerActive, not recruitingPhase 1/2Janssen Research & Development, LLCNCT05488314Written as Capmatinib
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedPhase 3Institut National de la Santé Et de la Recherche Médicale, FranceNCT03784014Written as Capmatinib
- Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationCompletedPhase 2Novartis PharmaceuticalsNCT04677595Written as Capmatinib
- Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLCTerminatedPhase 2Novartis PharmaceuticalsNCT04926831Written as capmatinib
- Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis TestTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT05243641Written as Capmatinib
- Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).TerminatedPhase 1Novartis PharmaceuticalsNCT03742349Written as capmatinib
- Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationTerminatedPhase 3Novartis PharmaceuticalsNCT04427072Written as Capmatinib
- Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%TerminatedPhase 2Novartis PharmaceuticalsNCT04139317Written as Capmatinib
- Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.TerminatedPhase 2Novartis PharmaceuticalsNCT01737827Written as INC280
- Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET AlterationsWithdrawnPhase 2Timothy Burns, MD, PHDNCT05567055Written as Capmatinib
- Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping MutationTerminatedPhase 1Collin BlakelyNCT05435846Written as Capmatinib
- Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)CompletedPhase 2Novartis PharmaceuticalsNCT02414139Written as Capmatinib
- LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedPhase 2PfizerNCT02159066Written as INC280
- Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line TherapyTerminatedPhase 3Novartis PharmaceuticalsNCT04816214Written as Capmatinib
- INC280 Combined With Bevacizumab in Patients With Glioblastoma MultiformeCompletedPhase 1SCRI Development Innovations, LLCNCT02386826Written as INC280
See all 44 studies that test capmatinib →
Given in every arm · 6 — capmatinib is usual care beside what is tested
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT05642572Written as Capmatinib
- Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneActive, not recruitingPhase 2Novartis PharmaceuticalsNCT03040973Written as Capmatinib
- Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCActive, not recruitingPhase 1Novartis PharmaceuticalsNCT03333343Written as INC280
- Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping MutationsTerminatedPhase 2Novartis PharmaceuticalsNCT04323436Written as Capmatinib
- Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaCompletedPhase 2Novartis PharmaceuticalsNCT03484923Written as INC280
- Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent GlioblastomaTerminatedPhase 1/2Novartis PharmaceuticalsNCT01870726Written as INC280
Codes
What other systems call capmatinib · ClinicalTrials.gg INT000595
- MeSH (NLM) C000613976capmatinibConfirmed NLM, Wikidata
- UNII (FDA) TY34L4F9OZCAPMATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2362165One source FDA
- Wikidata Q27075685capmatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90564CapmatinibOne source FDA
- DrugBank DB11791One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000613976 | capmatinib | Confirmed NLM, Wikidata |
| UNII (FDA) | TY34L4F9OZ | CAPMATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2362165 | — | One source FDA |
| Wikidata | Q27075685 | capmatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90564 | Capmatinib | One source FDA |
| DrugBank | DB11791 | — | One source Wikidata |
Also registered as capmatinib hydrochloride (UNII C2A374O70X · RxNorm 2362259), capmatinib hydrochloride anhydrous (UNII Z0V2EW20JR), cmc-583 (UNII PZ22FPE9O7) and cnj-294 (UNII DD8K9FL3YS).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.